Carmot Therapeutics Inc.
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2023 | $150 M | No. 5 | $50 to $250 million | equity | SEC | |
| Jul 2022 | $161 M | No. 4 | $50 to $250 million | equity | SEC | |
| Sep 2020 | $26 M | No. 3 | $10 to $50 million | equity | SEC | |
| Aug 2017 | $11 M | No. 2 | $10 to $50 million | equity | SEC | |
| Apr 2010 | $2 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Carmot Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2023).
SEC Form D · Jun 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2023
That is all the official record says: Carmot Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: the address on record now leads to another company's site.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Franklin Biotechnology Discovery Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, Jul 2026) | SEC Form N-PORT |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 25 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Heather K. Turner | Executive officer | Jun 2023 |
| Stig K. Hansen | Executive officer | Aug 2022 |
| Daniel A. Erlanson | Executive officer | Aug 2017 |
| Aetna Wun K. Trombley | Director | Jun 2023 |
| Anne K. Phillips, M.D. | Director | Jun 2023 |
| Heather K. Turner | Director | Jun 2023 |
| Peter K. Svennilson | Director | Jun 2023 |
| Stig K. Hansen, Ph.D. | Director | Jun 2023 |
| Tim K. Kutzkey | Director | Jun 2023 |
| Timothy K. Garnett | Director | Jun 2023 |
| Stig K. Hansen | Director | Aug 2022 |
| Tim K. Kutzky | Director | Oct 2020 |
| Aetna Wun Trombley | Director | Aug 2017 |
| Daniel A. Erlanson | Director | Aug 2017 |
| Larry K. Lasky | Director | Aug 2017 |
| Magnus K. Persson | Director | Apr 2010 |
About
Company in San Francisco, United States.